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Combined expression of A1 and A20 achieves optimal protec-
tion of renal proximal tubular epithelial cells.
Background. Apoptotic death of renal proximal tubular ep-
ithelial cells (RPTECs) is a feature of acute and chronic re-
nal failure. RPTECs are directly damaged by ischemia, inflam-
matory, and cytotoxic mediators but also contribute to their
own demise by up-regulating proinflammatory nuclear factor-
kappaB (NF-jB)–dependent proteins. In endothelial cells, the
Bcl family member A1 and the zinc finger protein A20 have re-
dundant and dual antiapoptotic and anti-inflammatory effects.
We studied the function(s) of A1 and A20 in human RPTECs
in vitro.
Methods. Expression of A1 [reverse transcription-polym-
erase chain reaction (RT-PCR) and A20 (Northern and West-
ern blot analysis)] in RPTECs was evaluated. A1 and A20
were overexpressed in RPTECs by recombinant adenoviral-
mediated gene transfer. Their effect upon inhibitor of NFjB
alpha (IjBa) degradation (Western blot), NF-jB nuclear
translocation [electrophoretic mobility shift assay (EMSA)],
up-regulation of intercellular adhesion molecule-1 (ICAM-
1) [fluorescence-activated cell sorter (FACS)] and mono-
cyte chemoattractant protein-1 (MCP-1) (Northern blot)
and apoptosis [terminal deoxynucleotiddyl transferase (TdT)-
mediated deoxyuridine triphosphate (dUTP) nick-end label-
ing (TUNEL)] and FACS analysis of DNA content) was
determined.
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Results. A1 and A20 were induced in RPTECs as part of
the physiologic response to tumor necrosis factor (TNF). A20,
but not A1, inhibited TNF-induced NF-jB activation by pre-
venting IjBa degradation, hence subsequent up-regulation of
the proinflammatory molecules ICAM-1 and MCP-1. Unex-
pectedly, A20 did not protect RPTECs from TNF and Fas-
mediated apoptosis while A1 protected against both stimuli.
Coexpression of A1 and A20 in RPTECs achieved additive anti-
inflammatory and antiapoptotic cytoprotection.
Conclusion. A1 and A20 exert differential cytoprotective ef-
fects in RPTECs. A1 is antiapoptotic. A20 is anti-inflammatory
via blockade of NF-jB. We propose that A1 and A20 are both
required for optimal protection of RPTECs from apoptosis
(A1) and inflammation (A20) in conditions leading to renal
damage.
Acute renal failure (ARF) and chronic renal failure
(CRF) are associated with damage to the tubular epithe-
lial cells [1–3]. ARF is still associated with an unaccept-
ably high rate of morbidity and mortality [4]. The most
common cause of ARF is renal hypoperfusion and sub-
sequent ischemia/reperfusion (I/R) injury which culmi-
nates in the loss of functioning tubular epithelial cells,
a process referred to as acute tubular necrosis (ATN)
[4]. Although the term ATN is still used to describe the
pathology of ARF, this is a misnomer because both apop-
totic and necrotic cell death occur along with desquama-
tion and loss of viable epithelial cells [5]. Recent evidence
indicates that apoptotic pathways, including endonucle-
ase activation, mitochondrial damage, and caspase ac-
tivation, contribute to renal tubular injury [6, 7]. Local
inflammation aggravates the damage associated with
acute and chronic renal diseases through production of
tumor necrosis factor (TNF), monocyte chemoattractant
protein-1 (MCP-1), and increased expression of the adhe-
sion molecule intercellular adhesion molecule-1 (ICAM-
1), further recruiting leukocytes to the site of injury and
1520
Kunter et al: Expression of A1 and A20 achieves optimal protection of RPTECs 1521
enhancing apoptotic death of renal tubular epithelial cells
[8]. Apoptosis has been documented in both the proximal
and distal tubular cells during I/R injury and CRF, but be-
cause of its marked sensitivity to hypoxia the S3 segment
of proximal tubules is the preferential site for apoptotic
cell death [3, 5].
Whatever the pathology that leads to renal epithelial
cell loss, it is often the response of the cell to this injury
that determines its fate. Cells respond to a variety of
stresses by activating the transcription of a battery of
“acute phase” or stress response genes. The transcription
factor nuclear factor-kappaB (NF-jB) is a key modula-
tor of this rapid stress response [9]. NF-jB is usually se-
questered in the cytoplasm in association with its inhibitor
inhibitor of NFjB alpha (IjBa) [10]. In response to in-
flammatory stimuli, IjBa is degraded allowing transloca-
tion of NF-jB to the nucleus and immediate, early gene
expression of proinflammatory proteins such as ICAM-1
and MCP-1 that amplify the inflammatory process and
damage to the kidney [11]. In addition to triggering in-
flammatory responses, NF-jB activation simultaneously
up-regulates a set of cytoprotective genes aimed at pro-
tecting cells from inflammatory insults [12, 13]. The bcl
family member A1 and the zinc finger protein A20 qual-
ify in this category [14, 15]. A1 is a bcl family member,
originally identified as a hematopoietic-specific early re-
sponse gene induced upon stimulation with granulocyte
monocyte-colony-stimulating factor (GM-CSF) [16]. Fur-
ther studies demonstrated A1 expression in other cell
types such as endothelial cells, smooth muscle cells, lung,
and fetal liver [16, 17]. In endothelial cells, A1 is induced
in response to proinflammatory stimuli, protects them
against TNF- and ceramide-mediated apoptosis [18, 19]
and prevents endothelial cell activation through inhibi-
tion of NF-jB [14] and nuclear factor for activated T
cells (NFAT) [Badrichani et al, manuscript in prepara-
tion]. Interestingly, NF-jB activation is required for A1
expression which suggests that A1 is part of a negative
down-regulatory loop of NF-jB activation [14].
A20 was originally identified as a TNF-inducible gene
product in endothelial cells [20]. A20 is expressed in a va-
riety of cell types in response to many stimuli, including
interleukin (IL)-1, CD40 crosslinking, and lipopolysac-
charide (LPS) [21–24]. We have shown that A20 serves
a broad cytoprotective function in endothelial cells by
inhibiting apoptosis and down-regulating inflammatory
responses via inhibition of the transcription factor NF-
jB [15, 25, 26]. The anti-inflammatory function of A20 is
well documented in A20 knockout mice, which are born
cachectic and die within 3 weeks of birth as a result of
unfettered inflammation [27]. A20, like A1, is an NF-jB–
dependent gene serving as part of a negative regulatory
loop critical for modulation of cell response to injury.
In this study we questioned whether A1 and A20
are expressed in renal proximal tubular epithelial cells
(RPTECs) in response to inflammatory stimuli and, if so,
whether they exert anti-inflammatory and antiapoptotic
effects in these cells which would prompt their use as
therapeutic tools to limit renal damage.
METHODS
Reagents
Human recombinant TNF-a (referred to as TNF in the
text) was purchased from R&D Systems (Minneapolis,
MN, USA); anti-Fas (a-Fas) IgM antibody CH-11 from
Kamiya Biomedical Company (Seattle, WA, USA); the
control mouse IgM antibody from Accurate Chemical &
Scientific Corporation (Westbury, NY, USA); and cyclo-
heximide and actinomycin D from Sigma Chemical Co.
(St. Louis MO, USA).
Cell culture
Primary human RPTECs were purchased from Clo-
netics (BioWhittaker, Inc., Walkersville, MD, USA), cul-
tured according to the manufacturer’s instructions and
used at passages 6 to 8. Identity and purity of RPTECs
were confirmed by staining for c-glutamyltransferase, a
selective marker of the brush border of human RPTECs.
Recombinant adenoviral vectors
The recombinant adenoviral vectors encoding human
A20 (rAd.A20), porcine IjBa (rAd.IjBa) and hemag-
glutinin A (HA)-tagged human A1 (rAd.A1) were gener-
ated in our laboratory [15]. The control adenoviral vector
encoding b-galactosidase (rAd.b-gal) was a kind gift from
Dr. R. Gerard (University of Texas Southwestern Med-
ical Center) and is an adequate control for adenovirus
infection. The A20 expression plasmid used to generate
the rAd.A20 was a kind gift from Dr. V. Dixit (Genentech
Inc., CA, USA). The recombinant adenoviruses were pro-
duced in the embryonic 293 kidney cell line [American
Type Culture Collection (ATCC), Rockland, MD, USA],
purified and titered as described [15]. Expression of the
transgenes in RPTECs was analyzed by immunohisto-
chemistry cytospins using a rabbit anti-A20 polyserum
(1/1000) generated in our laboratory (rAd.A20), a rat
anti-HA IgG1 monoclonal antibody (rAd.A1) (Roche
Molecular Biochemicals, Indianapolis, IN, USA) and X-
galactosidase (X-gal) staining (rAd.b-gal) according to
previously described methods [15, 24].
Total protein extraction and Western blot analysis
RPTECs were harvested, washed with phosphate-
buffered saline (PBS) then lysed in radioimmunopre-
cipitation assay (RIPA) buffer as described [28]. Fifteen
to 20 lg of protein were resolved on reducing sodium
dodecyl sulfate (SDS) polyacrylamide gels (12.5%) and
Western blot analysis were conducted using the follow-
ing antibodies: rabbit anti-IjBa IgG (1/1000 dilution)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) rabbit
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anti-A20 polyserum (1/3000) generated in our laboratory,
rat anti-HA IgG1 monoclonal antibody (Roche Molecu-
lar Biochemicals) and mouse anti-b-tubulin IgG2b mono-
clonal antibody (Chemicon International, Inc., Temecula,
CA, USA). Secondary antibodies included peroxydase-
conjugated donkey antirabbit IgG (H + L) (1/3000), goat
antimouse IgG (1/5000) and goat antirat IgG (1/3000)
(Pierce, Rockford, IL, USA). Detection was performed
by enhanced chemiluminescence (ECL) using a com-
mercially available kit (NEN Life Sciences, Boston, MA,
USA) according to the manufacturer’s instructions.
RNA extraction and Northern blot analysis
Total RNA was extracted from RPTECs using Tri-
zol reagent (Gibco BRL, Grand Island, NY, USA) [10].
Northern blot analysis was performed as described using
cDNA probes encoding for human A20 and human MCP-
1 [29]. In all experiments, a cDNA probe for human glyc-
eraldehyde triphosphate dihydrogenase (GAPDH) was
used to confirm equal RNA loading [15].
Nuclear extracts and electrophoretic mobility
shift assay (EMSA)
Nuclear proteins were extracted before and 2 hours
after stimulation with TNF (200 U/mL) as previously
described [15]. DNA binding reactions were performed
using radio-labeled NF-jB consensus oligonucleotide
(Promega Corp., Madison, WI, USA). For competition
assays, unlabeled NF-jB (specific competitor) or an un-
related activator protein-1 (AP-1) oligonucleotide (non-
specific competitor) were added to the reaction mixture.
Detection of apoptosis
Apoptotic cell death was evaluated by fluorescence-
activated cell sorter (FACS) analysis of DNA content us-
ing CELLQuestTM acquisition software (Becton Dickin-
son Immunocytometric Systems, San Jose, CA, USA) as
described [15]. Cells with a normal DNA content (>2 N)
were scored as viable, whereas cells with a hypodiploid
DNA content (<2 N) were scored as apoptotic.
Apoptosis was also detected in 1% paraformalde-
hyde fixed cytospins using the terminal deoxynucleotidyl
transferase (TdT)-mediated deoxyuridine triphosphate
(dUTP) nick-end labeling (TUNEL)–based ApopTag
red fluorescent kit or the ApopTag peroxydase plus
kit (Chemicon International Inc.). In brief, ApopTag
kits are based on TdT addition of digoxigenin-deoxy-
nucleoside triphosphate (dNTP) fragments to 3′ OH
DNA termini followed by labeling with peroxidase- or
rhodamine-linked antidigoxigenin antibodies and visual-
ization with either diaminobenzidine (DAB) followed by
light microscopy or fluorescence microscopy. Cells were
either counterstained with hematoxylin/eosin or labeled
with DAPI for nuclear staining.
Analysis of A1 mRNA expression by real time poly-
merase chain reaction (PCR) and semiquantitative re-
verse transcription (RT)-PCR
RPTECs were stimulated with TNF for 2 and 6
hours. Total mRNA was isolated (RNeasy Mini Proto-
col) (Qiagen, Santa Clara, CA, USA) and cDNA syn-
thesized (Superscript Pre-Amplification System for First
Strand cDNA Synthesis) (Life Technologies, Gibco BRL,
Gaithersburg, MD, USA) according to the manufacturer
instructions. PCR primers for human A1 were the follow-
ing: forward 5′- TGCGTCCTACAGATACCACAAC-3′
and reverse 5′-CCATCACTTGGTTGAATAGTGT-3′.
PCR reactions were carried on for 35 cycles. a-actin
primers were used as an internal control to correct for
cDNA integrity and to allow for semiquantitative analy-
sis.
Quantitative analysis of A1 mRNA was also per-
formed. A1 gene expression was analyzed by real-time
PCR using the ABI Prism 7900 HT sequence detec-
tor system (Applied Biosystems, Foster City, CA, USA).
Human A1 primers and probe (TaqMan MGB probes,
FAMTM dye-labeled) were purchased from Applied
Biosytem, Assays-on-Demand. Expression of the target
gene was normalized to that of the housekeeping gene,
18S ribosomal RNA.
Flow cytometry analysis of ICAM-1 expression
Surface expression of ICAM-1 was analyzed by flow cy-
tometry (FACScan) (Becton Dickinson, Immunocytom-
etry Systems) using a mouse antihuman ICAM-1 mon-
oclonal antibody (R&D Systems). An isotype matched
IgG1 monoclonal antibody was used as a control as de-
scribed [15].
Statistical methods
All statistical analyses were performed using the un-
paired t test or the Mann-Whitney nonparametric test
and the Instat analysis software.
RESULTS
A1 and A20 are part of the physiologic response of
RPTECs to injury
We evaluated whether A1 and A20 are up-regulated
in RPTECs following addition of TNF to mimic in vivo
inflammatory processes. Total RNA was extracted from
RPTECs before, 2, and 6 hours after addition of 200
U/mL of TNF. Because of technical difficulties for the
detection of A1 mRNA by Northern blot analysis, A1
mRNA was analyzed by RT-PCR. A1 was detected in
nonstimulated RPTEC cultures and up-regulated five-
fold (as assessed by densitometry of A1 mRNA corrected
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Fig. 1. A1 and A20 are induced in renal proximal tubular epithelial
cells (RPTECs) in response to inflammatory stimuli. (A) A1 mRNA
is induced 2 hours following stimulation with tumor necrosis factor
(TNF) in RPTECs at levels comparable to those detected in recom-
binant adrenoviral vectors encoding hemagglutinin A (HA)-tagged A1
(rAd.A1)–infected RPTECs at a multiplicity of infection (MOI) of 25 as
shown by reverse transcription-polymerase chain reaction (RT-PCR).
RT-PCR for b-actin showing equal signals in all groups allows for a
reliable semiquantitative analysis and for corrected densitometry anal-
ysis of A1 bands. (B) Northern blot analysis shows that A20 mRNA is
induced in RPTECs 2 hours after addition of TNF and decreases by 6
hours. Equal RNA loading was checked by probing for the housekeep-
ing gene glyceraldehyde triphosphate dehydrogenase (GAPDH). (C)
Western blot analysis shows that A20 protein is similarly up-regulated
3 hours following addition of TNF and starts declining by 6 hours. A20
protein levels in recombinant adrenoviral vectors (rAd.A20)-infected
RPTECs at a MOI of 25 reach 1.5-fold those detected 3 hours following
TNF as assessed by densitometry. Expression of the housekeeping pro-
tein b-tubulin checks loading and allows for a corrected densitometry
analysis of A20 protein expression. Results shown are representative
of two independent experiments. NI is noninfected.
by a-actin mRNA) 2 hours following addition of TNF
(Fig. 1A). A1 protein levels could not be detected due
to the unavailability of adequate antibodies. A20 mRNA
was evaluated by Northern blot analysis. A20 mRNA was
not detected in nonstimulated RPTECs and strongly in-
duced 2 hours following TNF (200 U/mL) stimulation
with a decline by 6 hours (Fig. 1B). A20 protein expres-
sion was evaluated by Western blot analysis using a rab-
bit antihuman A20 polyclonal antibody and showed little
A20 expression prior to TNF addition, a sixfold increase 3
hours following TNF stimulation and a decline by 6 hours
(Fig. 1C).
Overexpression of A20 but not A1 in RPTECs inhibits
TNF-induced NF-jB activation upstream of IjBa degra-
dation
We first established the multiplicity of infection
(MOI) necessary to achieve high transgene expression in
RPTECs. RPTECs were infected with rAd.A1, rAd.A20,
and the positive and negative controls rAd., IjBa and
rAd.b-gal at MOI ranging from 10 to 500. Optimal trans-
gene expression (>95% of RPTECs) without toxicity
was achieved 48 hours after infection using an MOI
of 25 which was considered optimal and subsequently
used in all experiments. In brief, RPTECs were infected
with increasing MOI starting at 10. Evaluation of trans-
gene expression was done 48 hours following infection
by immunohistochemistry and X-gal staining. Our results
demonstrate that a MOI of 25 reproducibly achieves ex-
pression of all transgenes in >95% of cultured RPTECs
(Fig. 2). At this MOI, mRNA levels of the A1 transgene
reached 1.4- to 1.5-fold those achieved in noninfected
RPTECs 2 hours following addition of TNF (Fig. 1A)
and A20 protein levels were 1.3- to twofold greater
than those detected in NI RPTEC 3 hours following
TNF stimulation, as evaluated by densitometry analy-
sis (Fig. 1C). These results indicate that at the MOI
used [25], adenoviral-mediated overexpression of A1 and
A20 were within an acceptable physiologic range, vali-
dating the relevance of data presented. We then sought
to determine whether A1 and A20 retain their NF-jB
inhibitory function in RPTECs. Nuclear and cytoplas-
mic extracts were recovered from noninfected, rAd.A1,
rAd.A20, rAd.IjBa( and rAd.b-gal–infected RPTECc
at 0, 15 minutes, and 2 hours following stimulation with
200 U/mL of TNF. EMSA analysis of nuclear extracts
from RPTECs overexpressing A20 or the positive con-
trol IjBa showed almost no TNF-inducible binding for
the NF-jB consensus oligonucleotides as opposed to the
high binding detected in noninfected and rAd. b-gal and
rAd.A1-infected RPTECs (Fig. 3A). These results in-
dicate that A20 but not A1 inhibits NF-jB transloca-
tion to the nucleus upon stimulation of RPTECs with
TNF. Expression of the transgenes A1, A20, and IjBa
was confirmed by Western blot analysis (Fig. 3). West-
ern blot analysis of IjBa expression in the cytoplasm
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Fig. 2. Recombinant adenovirus-mediated
gene transfer at a multiplicity of infection
(MOI) of 25 achieves expression of the trans-
gene in over 95% of cultured renal proximal
tubular epithelial cells (RPTECs). RPTECs
infected with recombinant adenoviral vectors
encoding hemagglutinin A (HA)-tagged
human A1 (rAd.A1), adenoviral vector
encoding b-galactosidase (rAd.b-gal), and
recombinant adenoviral vector encoding
A20 (rAd.A20) at MOI of 10 and 25 were
recovered 48 hours following the infection
and cytospins evaluated for the expression
of the transgenes by immunohistochemistry
using an anti-HA antibody directed against
HA-tagged A1, a rabbit polyclonal anti-
human A20 antiserum and X-galatosidase
(X-gal) staining. Results demonstrate that
expression of the transgene is detected in
>95% of the cells at a MOI of 25, whereas
only 80% to 85% of the cells express the
transgene at the MOI of 10. Noninfected
cells were used as controls. Results shown
are representative of over six independent
experiments. All pictures were taken using
light microscopy at 100×.
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Fig. 3. Expression of A20 but not A1 in-
hibits nuclear factor-kappaB (NF-jB) activa-
tion at a level upstream of IjBa degrada-
tion. (A) Nuclear extracts from noninfected
(NI) recombinant andenoviral vector encod-
ing hemagglutinin A (HA)-tagged human
A1 (rAd.A1), recombinant adenoviral vector
encoding A20 (rAd.A20), and recombinant
adenoviral vector encoding b-galactosidase
(rAd.b-gal)-infected renal proximal tubular
epithelial cells (RPTECs) were recovered
0 (control) (C) and 2 hours [tumor necro-
sis factor (TNF) (T)] after stimulation with
TNF. A20 expressing RPTECs had no TNF-
inducible binding activity for nuclear factor-
kappaB (NF-jB) in the nucleus, whereas
TNF-inducible binding activity is detected in
noninfected, rAd.A1, and rAd.b-gal–infected
RPTECs. Specificity of DNA binding was
tested by adding an excess of specific unla-
beled NF-jB competitor (SI) and an unre-
lated AP1 oligonucleotide as a nonspecific in-
hibitor (NSI). Expression of the A1 and the
A20 transgene was verified by Western blot
analysis. (B) Degradation of IjBa was as-
sessed by Western blot analysis. IjBa degra-
dation was demonstrated 15 minutes after ad-
dition of TNF in noninfected, rAd.A1, and
rAd.b-gal–infected RPTECs. Overexpression
of A20 or IjBa (used as a positive control)
in RPTECs totally inhibited IjBa degrada-
tion following TNF stimulation. Equal load-
ing was evaluated by checking for b-tubulin
levels. Results shown are representative of
three independent experiments.
demonstrated that overexpression of A20 but not A1
inhibited IjBa degradation following TNF stimulation
(Fig. 3B). A20-mediated blockade of NF-jB occurs at a
level upstream of IjBa degradation. In contrast, A1 does
not affect the activation of NF-jB in RPTECs. Equal
loading in Western blot analysis was confirmed by prob-
ing for the housekeeping protein b-tubulin (Fig. 3B).
Overexpression of A20 but not A1 inhibits the up-
regulation of the NF-jB–dependent genes ICAM-1 and
MCP-1 in RPTECs
Correlating with NF-jB blockade, A20 and IjBa
expression in RPTECs inhibited the TNF mediated up-
regulation of the proinflammatory NF-jB–dependent
genes ICAM-1 and MCP-1 (Fig. 4). In contrast, induction
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Fig. 4. Expression of A20 but not A1 in renal proximal tubular epithelial cells (RPTECs) inhibits up-regulation of the nuclear factor-kappaB (NF-
jB)–dependent genes intercellular adhesion molecule-1 (ICAM-1) and monocyte chemoattractant protein-1 (MCP-1). (A) ICAM-1 was evaluated
by fluorescence-activated cell sorter (FACS) analysis 24 hours following tumor necrosis factor (TNF) stimulation (empty histogram). Nontreated
RPTECs were used as control (filled histogram). Overexpression of A20 or IjBa totally inhibited the up-regulation of surface ICAM-1 expression. In
contrast, A1 expressing RPTECs up-regulated ICAM-1 surface expression to a similar extent to that detected in noninfected (NI) and recombinant
adenoviral vector encoding b-galactosidase (rAd.b-gal)–infected RPTECs. (B) MCP-1 was analyzed by Northern blot 2, 6, and 24 hours following
TNF stimulation. Overexpression of A20 and IjBa, but not A1 or b-gal inhibited the up-regulation of MCP-1 mRNA following stimulation with
TNF. The housekeeping gene glyceraldehyde triphosphate dehydrogenase (GAPDH) served as a control for equal loading. Results shown are
representative of three independent experiments.
of ICAM-1 and MCP-1 was similar in controls (nonin-
fected and rAd.b-gal) and rAd.A1-infected RPTECs
(Fig. 4). ICAM-1 surface expression was evaluated by
FACS analysis and showed an increase in mean fluores-
cence intensity (MFI) from 191 ± 29 (mean ± SD) to
577 ± 158, 354 ± 163 to 654 ± 164, and 325 ± 132 to
727 ± 144 in noninfected, rAd-b-gal, and rAd.A1-
infected RPTECs, respectively. Conversely, TNF-
mediated ICAM-1 up-regulation was totally abrogated
in rAd.A20 (MFI from 215 ± 17 to 193 ± 37) and
rAd.IjBa (MFI from 172 ± 10 to 129 ± 15) (N = 3
experiments done in duplicate) (P = 0.01 and 0.008,
respectively). Northern Blot analysis of MCP-1 mRNA
expression after stimulation with TNF showed similar
results. RPTECs overexpressing A1 or b-gal showed
marked up-regulation of MCP-1 mRNA 2 and 6 hours
after stimulation with TNF, whereas no up-regulation
was detected in RPTECs overexpressing A20 and
IjBa (Fig. 4B). These data suggest that expression in
RPTECs of A20, but not A1, inhibits their acquisition of
a proinflammatory phenotype.
Overexpression of A1 but not A20 protects RPTECs
from TNF-mediated apoptosis
We next questioned the effect of A1 and A20 on
RPTEC apoptosis. Noninfected and rAd.b-gal–infected
RPTECs treated with actinomycin D (666 nmol/L)
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Fig. 5. Overexpression of A1 but not A20 protects renal proximal tubular epithelial cells (RPTECs) from tumor necrosis factor (TNF)–mediated
apoptosis. RPTECs were either noninfected (NI) or infected with recombinant adenovirus vector encoding human antigen (HA)-tagged human A1
(rAd.A1), recombinant adenovirus vector encoding A20 (rAd.A20), recombinant adenovirus vector encoding IjBa (rAd.IjBa), or recombinant
adenovirus vector encoding b-galactosidase (rAd.b-gal) for 48 hours followed by treatment with the transcription inhibitor actinomycin D (Act. D)
alone, TNF alone, or actinomycin D and TNF for 16 hours. Apoptosis was assessed by DNA content analysis using flow cytometry (A◦ = apoptotic
cell fraction). A1 expression significantly protected RPTECs from actinomycin D/TNF–mediated apoptosis. In contrast, A20 and IjBa expressing
RPTECs were sensitized to actinomycin D/TNF–mediated apoptosis and showed a higher apoptotic rate than noninfected and rAd.b-gal–infected
RPTECs. Results shown are representative of three independent experiments. Apoptotic cell death was confirmed by terminal deoxynucleotidyl
transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) using the Apoptag red fluorometry-based kit with
DAPI counterstain. Dark dots represent intact nuclei stained with DAPI, whereas light dots represent apoptotic cells with fragmented DNA (100×
fluorescent microscopy). Results shown are representative of three independent experiments performed in duplicate.
followed by 200 U/mL of TNF for 16 hours underwent
apoptotic cell death. The percentage of apoptotic
RPTECs rose from 0.9 ± 0.8% (mean ± SD) to 9.9 ±
0.8% in noninfected RPTECs and from 1.5 ± 0.5% to 17.2
± 5.2% in rAd.b-gal–infected RPTECs. Overexpression
of A1 significantly (P = 0.0003) (N = 3 experiments per-
formed in duplicate) protected RPTECs from apoptosis
(Fig. 5), the rate of apoptotic RPTECs was 1.3 ± 0.5 in
nontreated cells and only increased to 4.2 ± 0.2 follow-
ing actinomycin D/TNF (Fig. 5). A20 expressing RPTECs
were not protected from actinomycin D/TNF-mediated
apoptosis. The percentage of apoptotic RPTECs was al-
ready increased in nontreated RPTECs reaching 8.6 ±
4.4%. Further increase in the apoptotic rate was noted
upon addition of actinomycin D or TNF alone and
was maximal when both were combined reaching 28.9
± 11.3%. This was significantly higher than the per-
centage of apoptotic cell death achieved in noninfected
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Fig. 6. Overexpression of A1 but not A20 protects renal proximal tubular epithelial cells (RPTECs) from Fas-mediated apoptosis. RPTEC were
either noninfected (NI) or infected with recombinant adenovirus vector encoding hemagglutinin A (HA)-tagged human A (1rAd.A1), recombinant
adenovirus vector encoding A20 (rAd.A20), recombinant adenovirus vector encoding IjBa (rAd.IjBa), or recombinant adenovirus vector encoding
b-galactosidase (rAd.b-gal) for 48 hours followed by treatment with cycloheximide (CHX) alone to inhibit protein synthesis, a-Fas antibody alone
or a combination of cycloheximide/a-Fas for 16 hours. Apoptosis was assessed by DNA content analysis using flow cytometry (A◦ = apoptotic
cell fraction). A1 expression significantly protected RPTECs from cycloheximide/a-Fas–mediated apoptosis. In contrast, A20 and IjBa expressing
RPTECs were sensitized to cycloheximide/a-Fas–mediated apoptosis and showed a higher apoptotic rate than noninfected and rAd.b-gal–infected
RPTECs. Results shown are representative of three independent experiments. Apoptotic cell death was confirmed by terminal deoxynucleotidyl
transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) using the Apoptag immunoperoxidase plus-based kit
with hematoxylin counterstain. Dark dots (arrows) represent apoptotic cells with fragmented DNA (100× fluorescent microscopy). Results shown
are representative of two independent experiments performed in duplicate.
and rAd.b-gal–infected RPTECs (N = 3) (P = 0.04).
Similar results were obtained in IjBa expressing
RPTECs. The percentage of apoptotic RPTECs follow-
ing actinomycin D/TNF treatment rose from 6.4 ± 4.4%
to 25.7 ± 6.1% (Fig. 5). Because quantification of apop-
tosis by FACS analysis sometimes fails to correlate with
morphologic markers [30], we evaluated apoptotic cell
death by TUNEL using a fluorescence-based kit that de-
tects DNA breaks. Our results confirm those obtained
by FACS analysis and display comparable percentages of
apoptotic cells (Fig. 5).
Overexpression of A1 but not A20 protects RPTECs
from Fas-mediated apoptosis
To determine whether the effect of A1 and A20
upon apoptosis was limited or not to TNF, RPTECs
were treated with another apoptotic stimulus (i.e.,
Fas cross-linking). RPTEC treated with cycloheximide
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Fig. 7. A1 is induced in renal proximal tubu-
lar epithelial cells (RPTECs) in a nuclear
factor-kappaB (NF-jB)–dependent manner.
(A) Noninfected (NI) RPTECs and RPTECs
infected with recombinant adenoviral vector
encoding hemagglutinin A (HA)-tagged hu-
man A (1rAd.A1), recombinant adenoviral
vector encoding A20 (rAd.A20), recombinant
adenoviral vector encoding IjBa (rAd.IjBa)
or the control recombinant adenoviral vector
encoding b-galactosidase (rAd.b-gal) were
treated with tumor necrosis factor (TNF) and
total RNA recovered 2 hours after. Real-
time polymerase chain reaction (PCR) anal-
ysis of A1 expression showed induction of
A1 in rAd.b-gal–infected cells 2 hours af-
ter TNF. This induction was totally blocked
in A20 and significantly blunted in IjBa ex-
pressing RPTECs. The specificity of the A1
PCR band was confirmed in RPTECs infected
with the rAd.A1 showing high amount of the
A1 transgene. All signals were corrected us-
ing the 18S ribosomal RNA. Data shown are
the mean ± SEM of relative corrected val-
ues of two experiments done in quadrupli-
cate. (B) These data were confirmed by semi-
quantitative reverse transcription (RT)-PCR
showing induction of A1 in noninfected and
rAd.b-gal–infected cells 2 and 6 hours after
TNF. This induction was blocked in A20 and
IjBa expressing RPTECs. The specificity of
the A1 PCR band was confirmed in RPTECs
infected with the rAd.A1 showing an equal
amount of the A1 transgene at all time points
studied. Equal signals for the housekeeping
gene b-actin were demonstrated in all sam-
ples demonstrating the integrity of cDNA and
allowing for comparative analysis. TC is tem-
plate control.
(2 lg/mL) followed by 1 lg/mL of a-Fas antibody for 16
hours underwent apoptotic cell death. The percentage
of apoptotic RPTECs rose from 0.9 ± 0.8% to 10.1 ±
1.2% in noninfected RPTECs and from 1.5 ± 0.5% to
15.2 ± 9.9% in rAd.b-gal–infected RPTECs. RPTECs
expressing A1 were partially protected from apoptosis
(Fig. 6). The rate of apoptotic RPTECs expressing
A1 was 1.3 ± 0.5% in nontreated cells and increased
to 6.9 ± 2.6% following cycloheximide/a-Fas (Fig. 6).
Expression of A20 in RPTECs did not protect and
even sensitized them to Fas-mediated apoptosis. The
percentage of apoptotis in RPTECs expressing A20
increased from 8.6 ± 4.4% to 49.6 ± 15.4% following
cycloheximide/a-Fas (N = 3 experiments performed in
duplicate) (P = 0.01). Similar sensitization to apoptosis
was detected in IjBa expressing RPTECs. The percent-
age of apoptotic RPTEC following cycloheximide/a-Fas
treatment rose from 6.4 ± 4.4% to 29.5 ± 12.3% (N
= 3) (P = 0.01) (Fig. 6). RPTECs were treated with a
control IgM antibody with or without cycloheximide
and showed a rate of apoptosis similar to with cyclo-
heximide alone (data not shown). Apoptotic cell death
was also evaluated by TUNEL and displayed simi-
lar results to those obtained by FACS analysis (Fig. 6).
These data demonstrate that A20 is not antiapoptotic
in RPTEC and may even sensitize them to TNF- and Fas-
mediated apoptosis. This later effect is likely related to
inhibition of NF-jB since a similar sensitization to apop-
tosis occurs in IjBa expressing RPTECs. In contrast, A1
maintains a potent antiapoptotic effect in RPTECs.
A1 is induced in RPTECs in a NF-jB–dependent manner
Sensitization of RPTECs to apoptosis when NF-jB
is blocked by overexpression of A20 or IjBa suggests
that protection is afforded by an NF-jB–dependent anti-
apoptotic gene. The Bcl family member A1 could be such
a candidate. A1 induction is NF-jB dependent, at least
in endothelial cells [14], and we have just demonstrated
that A1 is antiapoptotic in RPTECs. We sought to prove
that induction of A1 is NF-jB dependent in RPTECs. A1
mRNA induction was analyzed by real-time PCR in non-
infected RPTECs and RPTECs infected with rAd.A20,
rAd.IjBa, and rAd.bgal following stimulation with TNF.
Our data demonstrate that A1 is induced in noninfected
RPTEC and rAd.b-gal–infected RPTEC 2 hours follow-
ing stimulation with TNF. Relative A1 mRNA expression
corrected with the 18S ribosomal RNA increased from
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Fig. 8. Coexpression of A1 and A20 achieves additive anti-inflammatory and antiapoptotic effects. (A) IjBa degradation was assessed by Western
blot analysis. IjBa degradation was demonstrated 15 minutes after addition of tumor necrosis factor (TNF) in noninfected (NI) and recombinant
adenoviral vector encoding A1 and b-galactosidase (rAds.A1 + b-gal) expressing renal proximal tubular epithelial cells (RPTECs). Expression of
A20 in RPTECs infected with recombinant adenoviral vector encoding A20 and A1 (rAds.A20 + A1) or recombinant adenoviral vector encoding
A20 and b-galactosidase (rAds.A20 + b-gal) totally inhibited IjBa?degradation following TNF stimulation. Equal loading was evaluated by
checking for b-tubulin levels. Results shown are representative of four independent experiments. (B) TNF-mediated apoptosis was also evaluated
in the same treatment groups. RPTECs were either noninfected or infected with rAds.A1 + b-gal, rAdsA20 + b-gal, or rAds.A1 + A20 for 48 hours
followed by treatment with the transcription inhibitor actinomycin D (Act. D) alone, TNF alone, or the combination of both actinomycin D and TNF
for 16 hours. Apoptosis was assessed by DNA content analysis using flow cytometry (A◦ = apoptotic cell fraction). Expression of A1 significantly
protected RPTECs from TNF-mediated apoptosis when coexpressed with the control b-gal protein or with A20. In contrast, coexpression of A20
and b-gal sensitized RPTECs to TNF-mediated apoptosis and showed higher rate of apoptotic cells than noninfected RPTECs. Results shown are
representative of three independent experiments performed in triplicate (two experiments) and in duplicate (one experiment). Apoptotic cell death
was confirmed by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) using the
Apoptag red fluorometry-based kit with DAPI counterstain. Dark dots represent intact nuclei stained with DAPI, whereas light dots represent
apoptotic cells with fragmented DNA (100× fluorescent microscopy). Results shown are representative of two independent experiments performed
in duplicate.
25.2 ± 10.06 to 434.22 ± 125.33 and from 107.45 ± 40.66
to 417.14 ± 112.82 2 hours after addition of TNF in non-
infected and rAd.b-gal–infected RPTECs, respectively
(Fig. 7A). In contrast the induction of A1 was significantly
reduced in A20 and IjBa expressing RPTECs. Relative
A1 mRNA expression was not increased 2 hours after
addition of TNF in A20 expressing RPTECs with rela-
tive expression at 22 ± 6.31 prior to the addition of TNF
that remained at 14.90 ± 1.26 2 hours after addition of
TNF (P < 0.0001 vs. noninfected and rAd.b-gal–infected
RPTECs at 2 hours) and was significantly blunted in IjBa
expressing RPTECs rising from 50.91 ± 16.56 to 111.06
± 42 (P = 0.02 vs. noninfected and P = 0.06 vs. rAd.b-
gal–infected RPTECs at 2 hours) (Fig. 7A) (N = 2 experi-
ments run in quadruplicate as per the manufacturer’s rec-
ommendation). The specificity of the A1 real-time PCR
was guaranteed by the manufacturer but also confirmed
in RPTECs infected with the rAd.A1 which displayed a
very significant expression of A1 mRNA at all time points
tested (Fig. 6A). These results were further confirmed by
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semiquantitative analysis of A1 mRNA 2 and 6 hours
following TNF treatment as described earlier (Fig. 7B).
Coexpression of A1 and A20 achieves additive
anti-inflammatory and antiapoptotic cytoprotective
effects in RPTECs
Taken altogether, our data suggested that in RPTECs,
A1 and A20 were both required to limit inflammation and
apoptosis in response to injury. To prove this hypothe-
sis, we coinfected RPTECs with rAd.A1 and rAd.A20
(rAds.A1 + A20) at a MOI of 25 each. Forty-eight
hours following the infection, RPTECs were treated with
200 U/mL of TNF and cytoplasmic extracts were re-
covered at 0, 15 minutes, and 2 hours after addition of
TNF and evaluated for IjBa expression by Western blot
analysis. Coexpression of A1 and A20 abrogated TNF-
mediated IjBa degradation in RPTECs (Fig. 8A). As
expected, IjBa degradation was detected in noninfected
and rAds.A1 + b-gal but not in rAds.A20 + b-gal and
rAds.A1 + A20-infected RPTECs 15 minutes following
addition of TNF (Fig. 8A). This data indicate that the anti-
inflammatory effect of A20 was not altered in RPTECs
expressing other transgenes such as A1. We then eval-
uated the rate of apoptosis in RPTECs coinfected with
rAds.A1 + A20, rAds.A1 + b-gal, and rAds.A20 + b-
gal in response to actinomycin D/TNF. Our results in-
dicated that the antiapoptotic effect of A1 in RPTECs
was not altered by the coexpression of A20 or the con-
trol b-gal transgene. In fact, coexpression of A1 protected
A20 expressing RPTECs from apoptosis. The percentage
of apoptotic RPTECs rose from 5.97 ± 1.19% and 9.77
± 5.55% in noninfected and rAds.A20 + b-gal–infected
RPTECs treated with actinomycin D alone to 17.81 ±
5.04% and 23.01 ± 12.28%, respectively, after addition
of actinomycin D/TNF. Overexpression of A1 with ei-
ther A20 or b-gal significantly protected RPTECs from
apoptosis (P = 0.0005 and P = 0.0009 when compared
to noninfected cells and P = 0.006 when compared to
cells infected with rAdsA20 + b-gal). In actinomycin D–
treated rAds.A1 + A20 and rAds.A1 + b-gal–infected
RPTECs the percentage of apoptotic cells was 6.64 ±
1.99% and 6.11 ± 4.14%, respectively (mean ± SD of
three experiments, one performed in duplicate and two
in triplicate) (Fig. 8B). This rate of apoptosis did not
significantly increase following addition of actinomycin
D and TNF reaching 8.88 ± 2.39% in rAds.A1 + A20-
infected RPTECs and 8.47 ± 3.82% in rAds.A1 + b-
gal–infected cells (Fig. 8B). Evaluation of apoptosis by
TUNEL demonstrated comparable results to those ob-
tained by FACS analysis (Fig. 8B).
DISCUSSION
In the present study, we evaluated the function of two
cytoprotective genes A1 and A20 in RPTECs.
We demonstrated that A1 and A20 are induced in
RPTECs in response to inflammatory stimuli. TNF was
preferentially used as the activating stimulus to RPTECs
because it is known to mediate kidney damage incurred
during CRF, I/R injury, and sepsis [31, 32]. At sites of
injury, TNF is produced by activated monocytes and
macrophages and is also locally released from resident
renal cells, such as glomerular mesangial cells [33]. El-
evated in situ TNF levels promote renal dysfunction by
direct cytotoxicity and indirectly by aggravating inflam-
mation and ischemia through recruitment of neutrophils
and monocytes and promotion of vasoconstriction [34,
35]. In addition, expression of both A20 and A1 in
RPTECs requires NF-jB activation, indicating that these
genes could be part of a regulatory response to injury [13].
Overexpression of A20, but not A1, achieved a potent
anti-inflammatory effect via blockade of NF-jB activa-
tion, identifying A20 as an endogenous NF-jB antagonist
that is part of a negative regulatory loop limiting the in-
flammatory response in RPTECs. This agrees with the po-
tent anti-inflammatory function of A20 in other cell types,
including vascular endothelial cells, hepatocytes, and b
cells and with the unfettered inflammation in the liver and
kidney of A20-deficient mice [15, 23, 24]. Overexpres-
sion of A20 in RPTECs also prevented the up-regulation
of two NF-jB–dependent downstream target genes cen-
tral to the pathogenesis of ARF and CRF, ICAM-1 and
MCP-1. In hypoxic conditions and during ARF and CRF,
ICAM-1 and MCP-1 are induced in RPTECs and serve
to recruit monocytes to the site of injury, perpetuating
inflammation and aggravating injury [36–38]. ICAM-1–
null mice are protected against acute ischemic renal in-
jury [39]. In contrast to A20, overexpression of A1 did not
affect TNF-mediated NF-jB activation; hence, it failed to
promote any anti-inflammatory effect. This discrepancy
between the inhibitory effect of A1 upon NF-jB activa-
tion in endothelial cells versus none in RPTECs argues
for a cell type–specific anti-inflammatory function for this
gene [14].
We next studied the antiapoptotic potential of A1 and
A20 in RPTECs. Apoptosis of renal tubular epithelial
cells has been documented during I/R injury and CRF [5].
Administration of insulin-like growth factor-1 (IGF-1) or
the pan-caspase inhibitor ZVAD-fmk in an experimen-
tal model of I/R injury protected renal tubular cells from
apoptosis and prevented local inflammation, suggesting
that apoptosis of these cells is a central event potentiat-
ing inflammation and subsequent tissue damage during
I/R injury [40]. We tested the effect of A1 and A20 over-
expression in RPTECs upon two apoptotic stimuli, TNF
and the death receptor Fas [31, 41]. TNF, via its TNF-
RI, and Fas have been implicated as major culprits in the
renal damage associated with I/R injury, CRF and ob-
struction induced renal damage [31, 42–44]. Despite the
fact that use of TNF alone or sole Fas cross-linking are
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not sufficient to induce apoptosis of RPTECs in vitro, un-
less protein and RNA synthesis are blocked [45], in vivo
Fas deficiency protects mice from I/R-induced apoptosis
of tubular epithelial cells and blockade of TNF improves
I/R injury [42, 46]. This apparent discrepancy between
resistance of RPTECs to Fas cross-linking and TNF in
vitro and their clear implication in their demise in vivo
suggests that RPTECs express a substantial number of in-
duced antiapoptotic proteins that may be altered in dis-
ease states such as I/R injury and CRF. This sensitizes
RPTECs to TNF- and Fas-mediated damage in vivo, a
phenomenon that we reproduce in vitro by using block-
ers of RNA and protein synthesis such as actinomycin
D and cycloheximide. In addition, the proximal tubular
epithelium is the main site for Fas expression in the nor-
mal rat and mouse kidney and the primary target of is-
chemic damage further suggests a cause and effect rela-
tionship between Fas expression and RPTEC apoptosis
in these experimental models [1]. Overexpression of A1
totally protected RPTECs from both actinomycin D/TNF
and cycloheximide/a-Fas–mediated apoptosis. A1 has al-
ready been shown to protect endothelial cells from TNF-
mediated apoptosis, but to our knowledge, this is the first
demonstration of a protective effect of A1 against Fas-
mediated apoptosis [18].
Unexpectedly, overexpression of A20 did not protect
from and rather sensitized RPTECs to TNF- and Fas-
mediated apoptosis. A20-mediated sensitization to apop-
tosis mirrored that seen in IjBa expressing RPTECs
suggesting that it resulted from blockade of NF-jB ac-
tivation. It is well established that blockade of NF-jB
activation by overexpression of IjBa or in p65 knockout
mice sensitizes cells to TNF-mediated apoptosis [47, 48].
This is consistent with the paradigm that NF-jB activa-
tion is required for the up-regulation of a certain num-
ber of antiapoptotic genes to protect cellular integrity in
the face of an inflammatory insult [13]. A1 and A20 are
part of this NF-jB–dependent set of cytoprotective genes
in endothelial cells. Endothelial cells overexpressing A1
and A20 are protected from apoptosis despite blockade
of NF-jB by these same genes [14, 15]. Moreover, co-
expression of A20 rescues IjBa expressing endothelial
cells from TNF-mediated apoptosis [15]. In this study, we
demonstrate that A20 does not afford this antiapoptotic
function in RPTECs and may even be proapoptotic in
this given cell type. The molecular basis of whether A20
is antiapoptotic or not in a given cell type is unknown.
Several avenues of research are being explored, includ-
ing cell type–specific binding partners or target molecules
for the novel A20 deubiquinating and ubiquitin ligase
functions [49, 50] or, alternatively, cell type–specific dif-
ferences in signaling pathways engaged by TNF or Fas
ligation. In lieu of A20, our data demonstrate that it is the
NF-jB–dependent bcl family member A1 that supports
protection of RPTECs from apoptosis. Coexpression of
A1 rescues A20 expressing RPTECs from TNF-mediated
apoptosis despite inhibition of NF-jB activation
by A20.
To our knowledge, this is the first study evaluating
the function of the cytoprotective genes A1 and A20 in
RPTECs and demonstrating their differential effects on
inflammation and apoptosis. A1 is an attractive gene ther-
apy candidate that can limit the loss of RPTECs following
acute I/R injury such as in the setting of cardiac surgery
or organ transplantation. A similar beneficial effect of
A1 overexpression in RPTECs could also be envisioned
in chronic renal diseases and to increase the life span
and preserve metabolic function of proximal tubular cells
seeded into a synthetic hemofiltration device of a bioarti-
ficial kidney [51]. On the other hand, the beneficial anti-
inflammatory effect of A20 in RPTECs is hampered by
its sensitizing effect to TNF- and Fas-mediated apoptosis
and precludes its therapeutic use, at least alone, in set-
tings such as I/R injury and CRF. We would rather like to
propose that a potential therapeutic approach to protect
RPTECs in the face of injury may be one that combines
A1 and A20 to achieve a strong anti-inflammatory effect
(A20) while protecting from apoptosis (A1).
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